HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alcaftadine Eye Drops For Allergies Available OTC In US With Allergan’s Lastacaft Launch

Executive Summary

Abbvie business starts sales of Lastacaft (alcaftadine solution/0.25%) eye drops, licensed from innovator Vistakon Pharmaceuticals, approved through an sNDA. Full switch removes Lastacaft from Rx sales in US.

You may also be interested in...



Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions

From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.

Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy

Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.

Bausch Health’s 2022 Growth Led By Business With Separation Coming As Soon As One Month

Canadian firm reports Bausch + Lomb full-year and fourth-quarter revenue growth earnings as preparations continue to divest the business. Consumer health led Bausch + Lomb’s segments.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel